Source: Red Star News Network
Red Star News Network (Reporter Li Huiying) reported on April 12 On April 12, the world's first clinical study of dental follicle stem cells to treat periodontal disease was launched in Chengdu, Sichuan, attracting a lot of attention. It is understood that stem cell treatment has become the most cutting-edge and promising research direction in current periodontal disease research. The launch of "the world's first clinical study of dental follicle stem cells in the treatment of periodontal disease" is not only a landmark breakthrough in the treatment of periodontal disease, but also a landmark event in China's stem cell industry, which means that dental follicle stem cells can be used for periodontal disease. The future of disease treatment is promising.
It is worth mentioning that a new start-up company called Chengdu Shilian Health Biotechnology Co., Ltd. played an important role in this. What kind of company is this? What cutting-edge technology is there? Today, at the "World's First Dental Follicle Stem Cell Clinical Research Project Briefing for Periodontal Disease Treatment" held at the Frontier Medical Center of Xinchuan Innovation and Technology Park, Chengdu High-tech Zone, the mystery of Shilian Health was unveiled.
is backed by West China and has a strong founding team.
Public information shows that World Union Health is a project established by the Chengdu High-tech Zone Government, Chengdu West China Cell Therapy Research Institute Co., Ltd. ( West China Hospital ), Sichuan West China Maternal and Child Health Technology Co., Ltd. ( West China Second Hospital ), Sichuan West China Oral Health Technology Co., Ltd. (West China Stomatological Hospital), Shanghai Pharmaceutical Group , and the team of Professor Tian Weidong, chief scientist of the National "973" and key R&D plan projects, jointly invested and initiated it, with a profound "background".
Among them, Tian Weidong, as executive director and chief scientist, is an industry benchmark leader. He has 38 years of clinical work experience and more than 20 years of accumulation of scientific research results in the field of stem cells and regenerative medicine. He is currently a second-level professor of Sichuan University and Doctoral supervisor, chief scientist of national “973” and key R&D projects, etc. The other founding team members of
are also professionals who have been deeply involved in the industry for many years and have many years of experience in stem cell research or industry experience. The team has been focusing on stem cell and regenerative medicine research for more than 20 years, and has achieved a number of basic theoretical breakthroughs and technological innovations in the fields of odontogenic stem cells, adipose stem cells and other fields. The strong team of
, coupled with its support from West China, enables Shilian Health not only to have legal and compliant qualifications and status, but also to have first-mover advantages in terms of core technology and industry layout.
Independent research and development strives to fill the gap in stem cell drugs in China
As a leader in the stem cell industry in Sichuan, Shilian Health has been committed to building a world-class and high-standard cell technology and cell drug research and development and transformation application in Chengdu Frontier Medical Center since its establishment. Platform, the world's first allogeneic human dental follicle stem cell preparation independently developed has passed three batches of quality review inspections by the State Food and Drug Administration and the Central Inspection Institute, and has been successfully registered with the National Health Commission in 2022. Now, together with Sichuan University West China Stomatological Hospital and Peking University Stomatological Hospital, we are launching the world's first clinical study of allogeneic dental follicle stem cells for the treatment of periodontal disease, striving to fill the gap in stem cell drugs in China.
At the same time, the company will subsequently conduct cell drug research and development and clinical treatment technology transformation in spinal cord injury repair, premature ovarian failure , knee joint injury , and biological tooth root regeneration, and actively promote stem cell clinical research for other diseases. The pipeline products for biomedical aesthetics and oral regeneration are also about to be industrialized.
Phase 2 has clear goals and has built one database and two centers
In order to build a world-class, high-standard cell technology and cell drug research and development and transformation application platform, and consolidate the major scientific infrastructure for innovative development in the field of biomedicine in my country, Shilian Health has established Subsidiaries Sichuan Cell Bank Co., Ltd. and Sichuan Tianfu Cell Quality Testing and Evaluation Center Co., Ltd. have established a "one bank and two centers" cell industry innovation and development platform, namely, cell information resource library, regional cell preparation center, and cell quality testing and evaluation center to deploy scarce resources in the field of stem cells.
Tian Weidong
Tang Yingfeng, director and deputy general manager of Shilian Health and general manager of Sichuan Cell Bank Co., Ltd., introduced that Professor Tian Weidong, the founder and chief scientist of the platform, has devoted more than 20 years of research to the field of stem cells and regenerative medicine, and established the Oral Regeneration National Cooperating with local engineering laboratories and the Engineering Research Center of the Ministry of Education, it has laid a solid foundation for stem cell drug and technology research and development, company construction and achievement transformation. At present, Phase I of the overall project has completed the construction of a 3,500-square-meter platform, including a national cell information resource library, a regional cell preparation center with 6 independent cell production workshops that meet the "B+A" clean standard ( adult stem cells , iPS cells and Immune cell preparation), and Sichuan Tianfu Cell Quality Testing and Evaluation Center. Among them, the stem cell technology public technology platform for research and application and the comprehensive cell bank/regional cell preparation center have become the first government certification agencies. "At present, the company has initially formed a quality system that is traceable throughout the entire cycle of cell preparation, testing and storage, and a full-chain one-stop cell industry platform that integrates medicine, teaching, research and production. On the basis of existing resources and platforms ", it will build a high-tech biotechnology enterprise featuring precision medicine and precision health, integrating cell technology research and development, achievement transformation, technical services and talent training."
Reporters came to Shilian Health located in Chengdu Frontier Medical Center. Rows of automated cell storage tanks can be seen through the glass on the outside of the first floor of the office building. "This is the Sichuan Provincial Cell Bank. As a national cell information resource library, it can store cells for tens of millions of people." said Tang Yingfeng, deputy general manager of Shilian Health. After putting on their white coats and disposable shoe covers, reporters were led by staff to visit the cell preparation center, cell testing center, cell culture laboratory and other floors. In the workroom, researchers in white coats are busy working on high-end instruments and equipment, and cells are being prepared.
Tang Yingfeng revealed that Shilian Health will focus on major national development strategies and major scientific and technological innovation needs in the field of stem cells, collect and prepare 20 types of clinical-grade stem cell resources and 30 types of scientific research-grade stem cell resources within 6 years, and build a large collection of adult stem cells in my country. Strategic resource library.
At the same time, in the future, the company will use the national cell resource bank as the basis, the cell preparation center and the cell testing center as the conditions, and target the three major platforms of large-scale cell preparation GMP platform, cell quality testing public service platform, and cell clinical transformation platform. Cell production The four major systems of standardization, cell drug quality evaluation, cell technology innovation, and cell therapy clinical research services are the results, and an industrial layout of "one library, two centers, three platforms, and four systems" was finally established to actively promote the advent of stem cell drugs and treatment technologies.
"We will be based in Chengdu, facing Yunnan, Guizhou, Sichuan and Chongqing, and radiating throughout China. We will create a one-stop innovation incubation and achievement transformation demonstration base for the biomedical industry , promote the healthy development of the transformation and application of my country's stem cell resource industry, and further enhance my country's stem cell technology Transformation of independent innovation capabilities in the field of research," said Tang Yingfeng.
This article comes from [Red Star News Network] and represents only the author’s views. , the national party media information public platform , provides information release and dissemination services.
ID:jrtt
